Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRONCEL: Effect of Intravenous Iron Supplementation on Celiac Disease Remission
NCT05114278Phase 4Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ferric carboxymaltose in celiac disease (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Total villous recovery at 12 months. Started Jul 2022; status: terminated.
02
Drugs
ferric carboxymaltose
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT05114278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05114278.